JP2013502218A - 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 - Google Patents

組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 Download PDF

Info

Publication number
JP2013502218A
JP2013502218A JP2012525649A JP2012525649A JP2013502218A JP 2013502218 A JP2013502218 A JP 2013502218A JP 2012525649 A JP2012525649 A JP 2012525649A JP 2012525649 A JP2012525649 A JP 2012525649A JP 2013502218 A JP2013502218 A JP 2013502218A
Authority
JP
Japan
Prior art keywords
aptamer
tfpi
amino acid
acid residues
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012525649A
Other languages
English (en)
Japanese (ja)
Inventor
ロバート ジー． シャウブ，
キャスリーン マクギネス，
ジェニファー ネルソン，
ライアン ゲンガ，
エミリー ウォーターズ，
ジェフリー シー． クルス，
ジョン エル． ディーナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of JP2013502218A publication Critical patent/JP2013502218A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2012525649A 2009-08-18 2010-08-17 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用 Withdrawn JP2013502218A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US23493909P 2009-08-18 2009-08-18
US61/234,939 2009-08-18
US35337410P 2010-06-10 2010-06-10
US61/353,374 2010-06-10
US36636210P 2010-07-21 2010-07-21
US61/366,362 2010-07-21
US36776610P 2010-07-26 2010-07-26
US61/367,766 2010-07-26
PCT/US2010/045797 WO2011022427A1 (en) 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Publications (1)

Publication Number Publication Date
JP2013502218A true JP2013502218A (ja) 2013-01-24

Family

ID=43607310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012525649A Withdrawn JP2013502218A (ja) 2009-08-18 2010-08-17 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用

Country Status (17)

Country Link
US (1) US8252913B2 (enExample)
EP (1) EP2467167B1 (enExample)
JP (1) JP2013502218A (enExample)
KR (1) KR20120061086A (enExample)
CN (1) CN102869385A (enExample)
AU (1) AU2010284329B2 (enExample)
BR (1) BR112012003806A2 (enExample)
CA (1) CA2770762A1 (enExample)
CO (1) CO6531414A2 (enExample)
ES (1) ES2655589T3 (enExample)
IL (1) IL218048A0 (enExample)
IN (1) IN2012DN01984A (enExample)
MX (1) MX2012002133A (enExample)
NZ (1) NZ598557A (enExample)
RU (1) RU2012110221A (enExample)
SG (1) SG178408A1 (enExample)
WO (1) WO2011022427A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522419A (ja) * 2013-06-21 2016-07-28 イミジン， インコーポレイテッド 血液解析
JP2016529911A (ja) * 2013-09-09 2016-09-29 ソマロジック・インコーポレーテッド 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
WO2017094897A1 (ja) * 2015-12-04 2017-06-08 全薬工業株式会社 血中滞留性を改善した抗ｉｌ－１７アプタマー

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
AU2012214148A1 (en) * 2011-02-11 2013-08-29 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
KR20140066977A (ko) 2011-06-08 2014-06-03 미에드지나로도위 인스티투트 바이오로지 모레쿠라네지 아이 코모르코웨즈 서열-특이적 조작된 리보뉴클레아제 ｈ 및 ｄｎａ－ｒｎａ 하이브리드 결합 단백질의 서열 선호도를 측정하는 방법
EP2827910A2 (en) * 2012-03-22 2015-01-28 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
WO2015007880A1 (en) 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
EP4378487A3 (en) * 2015-06-23 2024-09-04 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN112442127A (zh) 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN115792231B (zh) * 2022-11-04 2023-07-25 中拓生物有限公司 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
PT1009413E (pt) 1997-09-05 2007-05-31 Univ California Utilização de oligonucleótidos imumoestimulantes para a prevenção ou tratamento da asma.
EP1020534B2 (en) * 1998-11-09 2011-01-05 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AU2003238772A1 (en) * 2002-05-31 2003-12-19 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2007014749A2 (en) 2005-07-29 2007-02-08 Universiteit Van Maastricht Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016522419A (ja) * 2013-06-21 2016-07-28 イミジン， インコーポレイテッド 血液解析
JP2016529911A (ja) * 2013-09-09 2016-09-29 ソマロジック・インコーポレーテッド 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
US10544419B2 (en) 2013-09-09 2020-01-28 Somalogic Inc. PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
JP2021072835A (ja) * 2013-09-09 2021-05-13 ソマロジック・インコーポレーテッド 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
JP7209025B2 (ja) 2013-09-09 2023-01-19 ソマロジック・オペレイティング・カンパニー・インコーポレイテッド 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
WO2017094897A1 (ja) * 2015-12-04 2017-06-08 全薬工業株式会社 血中滞留性を改善した抗ｉｌ－１７アプタマー
US11013756B2 (en) 2015-12-04 2021-05-25 Zenyaku Kogyo Co., Ltd. Anti-IL-17 aptamer having improved retention in blood

Also Published As

Publication number Publication date
MX2012002133A (es) 2013-02-15
EP2467167A4 (en) 2013-12-25
CA2770762A1 (en) 2011-02-24
CO6531414A2 (es) 2012-09-28
EP2467167A1 (en) 2012-06-27
WO2011022427A1 (en) 2011-02-24
AU2010284329A1 (en) 2012-03-29
AU2010284329B2 (en) 2015-04-16
US20110098345A1 (en) 2011-04-28
IN2012DN01984A (enExample) 2015-07-24
SG178408A1 (en) 2012-03-29
BR112012003806A2 (pt) 2016-11-16
EP2467167B1 (en) 2017-08-16
IL218048A0 (en) 2012-04-30
RU2012110221A (ru) 2013-09-27
CN102869385A (zh) 2013-01-09
KR20120061086A (ko) 2012-06-12
ES2655589T3 (es) 2018-02-20
NZ598557A (en) 2013-08-30
US8252913B2 (en) 2012-08-28

Similar Documents

Publication Publication Date Title
AU2010284329B2 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8598327B2 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US8283330B2 (en) Modulators of pharmacological agents
JP4718541B2 (ja) 改良された凝固因子調節剤
US20120149764A1 (en) Aptamers that bind thrombin with high affinity
US8318923B2 (en) Nucleic acid modulators of glycoprotein VI
JP6002691B2 (ja) 組織因子経路阻害剤に対するアプタマーおよび出血障害治療薬としてのそれらの使用
HK1171959A (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
HK1171959B (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US20150344533A1 (en) Nucleic acid modulators of glycoprotein vi
AU2012244176B8 (en) Modulators of pharmacological agents
AU2012244176B2 (en) Modulators of pharmacological agents
HK1131623B (en) Modulators of pharmacological agents
HK1256789A1 (zh) 用於治疗补体-相关失调的适体治疗

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20131105